Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment

OBJECTIVE: In MOBILITY (NCT01061736), sarilumab significantly reduced disease activity, improved physical function and inhibited radiographic progression at week 52 versus placebo in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate. We report 5-year safety, efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C, van der Heijde, Désirée, Lin, Yong, St John, Gregory, Wang, Sheldon, van Hoogstraten, Hubert, Gómez-Reino, Juan José, Kivitz, Alan, Maldonado-Cocco, José Antonio, Seriolo, Bruno, Stanislav, Marina, Burmester, Gerd R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691511/
https://www.ncbi.nlm.nih.gov/pubmed/31452928
http://dx.doi.org/10.1136/rmdopen-2018-000887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691511/
https://www.ncbi.nlm.nih.gov/pubmed/31452928
http://dx.doi.org/10.1136/rmdopen-2018-000887

Ejemplares similares